Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma

被引：0
|
作者：
Hatton, C. S. R. [1 ]
Peniket, A. [1 ]
Tusold, A. [1 ]
Collins, G. P. [1 ]
Joyner, M. [2 ]
Lee, R. [2 ]
Mouncey, P. [3 ]
Smith, P. [3 ]
Lee, S-M [4 ]
机构：
[1] John Radcliffe Hosp, Dept Haematol, Oxford OX3 9DU, England
[2] Univ Exeter, Royal Devon & Exeter Hosp, Dept Haematol, Exeter, Devon, England
[3] Canc Res UK UCL Canc Trials Ctr, Lymphoma Trials Off, London, England
[4] Univ Coll London Hosp, Dept Oncol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2009年 / 145卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
28
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [1] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [2] Selinexor in patients with relapsed or refractory diffuse large B -cell lymphoma (SADAL): a single -arm, multinational, multicentre, open -label, phase 2 trial
    Kalakonda, Nagesh
    Maerevoet, Marie
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Hamad, Nada
    Zijlstra, Josee M.
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Manuel Sancho, Juan
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros P.
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Chang, Hua
    Landesman, Yosef
    Joshi, Anita
    Wang, Hongwei
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Van den Neste, Eric
    Canales, Miguel A.
    LANCET HAEMATOLOGY, 2020, 7 (07): : E509 - E522
  • [3] Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study
    Jasielec, Jagoda
    Peace, David
    Edwards, Sarah
    Tolzien, Kathy
    Smith, Sonali M.
    Nabhan, Chadi
    BLOOD, 2013, 122 (21)
  • [4] Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
    Lin, Ningjing
    Sun, Xiuhua
    Zhou, Hui
    Zou, Liqun
    Zhou, Keshu
    Liu, Lihong
    Yang, Haiyan
    Hu, Kai
    Cai, Qingqing
    Liu, Yao
    Jin, Jie
    Zhang, Liling
    Li, Wenyu
    Guo, Ye
    Yang, Wei
    Luo, Feng
    Wang, Zhenguang
    Zhu, Rong
    Yang, Lei
    Song, Dan
    Song, Yuqin
    Zhu, Jun
    HAEMATOLOGICA, 2025, 110 (03) : 683 - 692
  • [5] Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Zhang, Xudong
    Feng, Xiaoyan
    Zhou, Zhiyuan
    Chang, Yu
    Li, Zhaoming
    Young, Ken H.
    Zhang, Mingzhi
    BLOOD, 2019, 134
  • [6] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [7] Open-Label, Single-Arm, Phase II Study of Everolimus in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Graham, Anne
    Ramchandren, Radhakrishnan
    BLOOD, 2011, 118 (21) : 1169 - 1169
  • [8] Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Lenz, Georg
    Hawkes, Eliza
    Verhoef, Gregor
    Haioun, Corinne
    Thye, Lim Soon
    Heo, Dae Seog
    Ardeshna, Kirit
    Chong, Geoffrey
    Christensen, Jacob Haaber
    Shi, Vivian
    Lippert, Susanne
    Niemeyer, Florian
    Piraino, Paolo
    Pena, Carol Elaine
    Buvaylo, Viktoriya
    Childs, Barrett H.
    Gorbatchevsky, Igor
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
    Ansell, Stephen M.
    Minnema, Monique C.
    Johnson, Peter
    Timmerman, John M.
    Armand, Philippe
    Shipp, Margaret A.
    Rodig, Scott J.
    Ligon, Azra H.
    Roemer, Margaretha G. M.
    Reddy, Nishitha
    Cohen, Jonathon B.
    Assouline, Sarit
    Poon, Michelle
    Sharma, Manish
    Kato, Kazunobu
    Samakoglu, Selda
    Sumbul, Anne
    Grigg, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) : 481 - +
  • [10] Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study
    Li, Zhiming
    Sun, Peng
    Cen, Hong
    Yang, Haiyan
    Huang, Rui
    Cai, Zhen
    Gu, Xuekui
    BLOOD, 2023, 142
12345